GlassScriptPhysician profile
Sarat Chandra Kunapuli
NPI 1295932978
$135,959.12
in general payments reported to CMS, 2019-2025
12 companies · $5,891 in 2025
The $5,891 reported for 2025 was more than what 84% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $21K · 2021: $19K · 2022: $27K · 2023: $13K · 2024: $9,685 · 2025: $5,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Travel and Lodging: $3,993 · Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,300.00 |
| Travel and Lodging | $3,993.41 |
| Food and Beverage | $1,459.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $133,486.47 | 2019-2025 | Mako, Triathlon, Insignia |
| Pacira Pharmaceuticals Incorporated | $1,751.71 | 2021-2025 | Zilretta |
| Globus Medical, INC. | $174.68 | 2024 | Actify |
| Pacira Therapeutics, INC. | $169.10 | 2019-2021 | |
| Orthalign INC | $146.45 | 2023 | Orthalign Plus |
| Zimmer Biomet Holdings, INC. | $87.28 | 2022 | |
| Heron Therapeutics, INC. | $44.58 | 2023 | Zynrelef |
| Depuy Synthes Sales INC. | $41.45 | 2022-2025 | Monovisc |
| Vertex Pharmaceuticals Incorporated | $27.68 | 2025 | |
| Ferring Pharmaceuticals INC. | $16.87 | 2025 | Euflexxa |
| Baudax Bio INC. | $12.85 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarat Kunapuli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.